{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:54:39Z","timestamp":1785704079205,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:50:44Z","timestamp":1781049044000},"page":"540-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Biological Implications of TP53 Abnormalities in Relapsed\/Refractory Multiple Myeloma: The DEDALO Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7842-3386","authenticated-orcid":false,"given":"Vittorio","family":"Montefusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cafro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Margiotta-Casaluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-3452","authenticated-orcid":false,"given":"Anna Benedetta","family":"Dalla Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1235","authenticated-orcid":false,"given":"Rita","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bertazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Vaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8248-2343","authenticated-orcid":false,"given":"Laura","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2026.05.013_bib0001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.05.013_bib0002","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.05.013_bib0003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","article-title":"The p53 proto-oncogene can act as a suppressor of transformation","volume":"57","author":"Finlay","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.clml.2026.05.013_bib0004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-pathol-042320-025840","article-title":"A balancing act: p53 activity from tumor suppression to pathology and therapeutic implications","volume":"17","author":"Wang","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.013_bib0005","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.05.013_bib0006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2026.05.013_bib0007","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.05.013_bib0008","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2026.05.013_bib0009","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Onco"},{"issue":"29","key":"10.1016\/j.clml.2026.05.013_bib0010","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"364","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.05.013_bib0011","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Lod\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.05.013_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.05.013_bib0013","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.05.013_bib0014","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.05.013_bib0015","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.clml.2026.05.013_bib0016","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.05.013_bib0017","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2026.05.013_bib0018","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-020-04384-w","article-title":"A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS\/SMM to newly diagnosed and relapsed multiple myeloma","volume":"100","author":"Oliva","year":"2021","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.clml.2026.05.013_bib0019","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.013_bib0020","unstructured":"US Dept of Health and Human Services - National Institutes of Health - National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed: June 29, 2026."},{"issue":"11","key":"10.1016\/j.clml.2026.05.013_bib0021","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San-Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.05.013_bib0022","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.05.013_bib0023","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.05.013_bib0024","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"issue":"10214","key":"10.1016\/j.clml.2026.05.013_bib0025","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.clml.2026.05.013_bib0026","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"D\u2019Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.013_bib0027","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173685","article-title":"Cell-free DNA from blood or bone marrow as alternatives to bone marrow cells for molecular diagnostics and monitoring of multiple myeloma","volume":"142","author":"Abelman","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.05.013_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070917","article-title":"DNA-repair gene mutations are highly prevalent in circulating tumour DNA from multiple myeloma patients","volume":"11","author":"Mithraprabhu","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:38Z","timestamp":1785701978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001734"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Biological Implications of TP53 Abnormalities in Relapsed\/Refractory Multiple Myeloma: The DEDALO Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}